Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Thrombocytopenia in Glioblastoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proof of newly diagnosed glioblastoma,~* Age: 18 and older,~* Information to patient and signed consent form,~* Indication for a  Stupp  protocol (cerebral focal radiotherapy and concomitant TMZ followed by adjuvant TMZ - 6 cycles),~* Patient with grade 3 or 4 TP during Temozolomide chemotherapy, regardless of when the onset of TP was: after completion of concomitant RT/CT, before adjuvant CT or during adjuvant CT and only if a minimum of 2 cycles are still planned,~* Normal initial platelets count (\> 100 000/mm3) before the start of Temozolomide during the RT/CT concomitant phase,~* Adequate haematological, renal, hepatic function at the time of inclusion visit,~* ECOG PS 0-2 (patients unable to walk because of a paralysis and who are up in a wheel chair will be considered as ambulatory for the evaluation of the ECOG performance status),~* Life expectancy \> 2 months,~* Patients covered by the French Health Insurance System,~* Negative pregnancy test at the time of inclusion visit,~* If required, effective contraception respecting criteria of CPMP/ICH/286/95 (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner).~Exclusion Criteria:~* Concomitant radiotherapy (Romiplostim will be started after the completion of the RT/CT concomitant phase),~* Other malignancies (prior hx malignancies),~* Any anterior systemic chemotherapy,~* Any known coagulation disease or known haematological disease even if resolved. Known hypercoagulate state (e.g., factor V Leiden, protein C defiency, protein S deficiency, PT 20201, antiphospholipid antibody syndrome...),~* Prior Romiplostim exposure or prior exposure to other TPO mimetics,~* History of thromboembolic disease \< 6 months. Treatment with anticoagulant such as Heparin or antivitamin K (LMWH as prophylactic treatment is authorized),~* Any other hemato-toxicity (anemia, neutropenia) requiring EPO or GCSF,~* Other causes of Temozolomide interruption (non haematological toxicities),~* Known hypersensitivity to any E-coli derived product,~* Participation to any other study during the last 30 days,~* Refusal to give written informed consent,~* Pregnancy or nursing,~* For all men and women of childbearing potential: Refusal or inability to use effective means of contraception,~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial,~* Persons protected by a legal regime (guardianship, trusteeship),~* Patients in emergency situations,~* Patients kept in detention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy